Current Progress on Assessing the Prognosis for Anti-N-Methyl-D-Aspartate Receptor (NMDAR) Encephalitis.
Journal
BioMed research international
ISSN: 2314-6141
Titre abrégé: Biomed Res Int
Pays: United States
ID NLM: 101600173
Informations de publication
Date de publication:
2020
2020
Historique:
received:
03
02
2020
accepted:
01
04
2020
entrez:
1
5
2020
pubmed:
1
5
2020
medline:
11
2
2021
Statut:
epublish
Résumé
Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis is the most common antineuronal antibody encephalitis in autoimmune encephalitis found at present. It has complex clinical manifestations such as psychiatric and behavioral abnormalities, seizures, movement disorders, consciousness, and autonomic dysfunction. The relationship between those manifestations and prognosis is unclear. Electroencephalography (EEG) is gradually becoming useful in the evaluation of the prognosis of anti-NMDAR encephalitis patients, while imaging and antibody testing have a limited prognostic value. Starting the patients on adequate treatments (such as immunotherapy) in a timely fashion has a positive impact on their prognosis. Nevertheless, research on the prognosis of anti-NMDAR encephalitis remains scarce. Here, we review the current advances of prognosis-related research from the clinical manifestations of the disease and auxiliary examinations such as EEG, magnetic resonance imaging (MRI), 18F fluorodeoxyglucose positron emission tomography (FDG-PET), and antibody measurement. In addition, we also discuss the impact of different treatment options on prognosis. In-depth research on the prognosis of patients with anti-NMDAR encephalitis will contribute to a better understanding of this disease, leading to better treatments options and, ultimately, a better prognosis.
Identifiants
pubmed: 32352007
doi: 10.1155/2020/7506590
pmc: PMC7178504
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
7506590Informations de copyright
Copyright © 2020 Hao Wang and Zheng Xiao.
Déclaration de conflit d'intérêts
The authors declare that there is no conflict of interest regarding the publication of this paper.
Références
Clin Neurophysiol. 2017 Jul;128(7):1227-1233
pubmed: 28527387
Adv Pharmacol. 2018;82:235-260
pubmed: 29413523
JAMA Neurol. 2013 Sep 1;70(9):1133-9
pubmed: 23877059
J Clin Exp Neuropsychol. 2018 Apr;40(3):234-252
pubmed: 28585453
Brain. 2010 Jun;133(Pt 6):1655-67
pubmed: 20511282
J Clin Neurosci. 2018 Jun;52:54-59
pubmed: 29605275
Epilepsia. 2019 Mar;60(3):452-463
pubmed: 30740690
J Clin Neurol. 2014 Apr;10(2):157-61
pubmed: 24829602
Neurology. 2016 May 3;86(18):1683-91
pubmed: 27037228
N Engl J Med. 2018 Mar 1;378(9):840-851
pubmed: 29490181
Acta Psychiatr Scand. 2018 Nov;138(5):401-408
pubmed: 29992532
Lancet Neurol. 2013 Feb;12(2):157-65
pubmed: 23290630
Am J Respir Crit Care Med. 2017 Feb 15;195(4):491-499
pubmed: 27552490
Epileptic Disord. 2013 Jun;15(2):166-70
pubmed: 23773862
Neurol Neuroimmunol Neuroinflamm. 2018 Oct 30;6(1):e514
pubmed: 30568992
Neurotherapeutics. 2016 Oct;13(4):824-832
pubmed: 27215218
BMC Neurol. 2014 Jun 20;14:136
pubmed: 24950993
J Clin Neurol. 2016 Jan;12(1):1-13
pubmed: 26754777
Neurology. 2011 Sep 6;77(10):996-9
pubmed: 21865579
Neurology. 2019 May 7;92(19):e2185-e2196
pubmed: 30979857
Acta Neuropathol. 2002 May;103(5):509-15
pubmed: 11935268
J Neurol Sci. 2015 May 15;352(1-2):79-83
pubmed: 25847017
Dev Med Child Neurol. 2015 Jan;57(1):95-9
pubmed: 25040285
Pharmacol Biochem Behav. 2004 Jul;78(3):483-93
pubmed: 15251257
Brain. 2015 Jan;138(Pt 1):94-109
pubmed: 25392198
Neurol Neuroimmunol Neuroinflamm. 2018 Dec 26;6(2):e529
pubmed: 30697582
J Autoimmun. 2019 Jan;96:24-34
pubmed: 30595145
Med Clin (Barc). 2018 Jul 23;151(2):71-79
pubmed: 29183618
Clin Neurophysiol. 2013 Dec;124(12):2354-61
pubmed: 23830005
Expert Rev Neurother. 2015;15(12):1391-419
pubmed: 26559389
Acta Neurol Scand. 2017 Dec;136(6):738
pubmed: 29105077
Case Rep Neurol Med. 2016;2016:7967526
pubmed: 27190663
Clin Nucl Med. 2016 May;41(5):366-70
pubmed: 26914566
Clin EEG Neurosci. 2017 Jan;48(1):48-53
pubmed: 27068513
Pediatr Neurol. 2016 Feb;55:37-45
pubmed: 26724889
Brain. 2000 Jul;123 ( Pt 7):1431-41
pubmed: 10869055
JAMA Neurol. 2016 Jun 1;73(6):706-13
pubmed: 27111481
Transl Neurosci. 2019 Oct 02;10:241-243
pubmed: 31637048
Eur J Neurol. 2016 Mar;23(3):621-9
pubmed: 26563553
Lancet Neurol. 2011 Jan;10(1):63-74
pubmed: 21163445
Ann Neurol. 2007 Jan;61(1):25-36
pubmed: 17262855
Mov Disord. 2013 Apr;28(4):543-7
pubmed: 23400857
Neurology. 1998 Dec;51(6 Suppl 5):S2-8
pubmed: 9851723
J Neuroinflammation. 2012 May 16;9:93
pubmed: 22591862
Neurol Neuroimmunol Neuroinflamm. 2016 Feb 26;3(2):e207
pubmed: 26977423
Epilepsia. 2017 Dec;58(12):2104-2111
pubmed: 29098690
Clin Chim Acta. 2015 Jan 1;438:90-7
pubmed: 25149104
Lancet Neurol. 2016 Apr;15(4):391-404
pubmed: 26906964
J Neurosci. 2010 Apr 28;30(17):5866-75
pubmed: 20427647
Neurology. 2014 Feb 18;82(7):556-63
pubmed: 24443452
Arch Clin Neuropsychol. 2019 Nov 27;34(8):1309-1319
pubmed: 30418503
Ann Neurol. 2013 Aug;74(2):284-96
pubmed: 23686722
J Neuropsychiatry Clin Neurosci. 2019 Winter;31(1):70-79
pubmed: 30376787
Acta Neurol Scand. 2018 Feb;137(2):277-282
pubmed: 29023630
Am J Case Rep. 2018 Oct 12;19:1216-1221
pubmed: 30310049
Neurology. 2012 Sep 11;79(11):1094-100
pubmed: 22933737
Clin Infect Dis. 2012 Apr;54(7):899-904
pubmed: 22281844
J Int Neuropsychol Soc. 2016 Sep;22(8):828-38
pubmed: 27546201
Lancet Neurol. 2008 Dec;7(12):1091-8
pubmed: 18851928
Clin Auton Res. 2006 Feb;16(1):18-28
pubmed: 16477491
Neurol Neuroimmunol Neuroinflamm. 2015 Apr 02;2(3):e92
pubmed: 25909091
Lancet Neurol. 2019 Nov;18(11):1045-1057
pubmed: 31326280
Lancet Neurol. 2014 Feb;13(2):167-77
pubmed: 24360484